Work

Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.9099

Authors: Pasi A. Janne, Suresh S. Ramalingam, James Chih-Hsin Yang, Gregory J. Riely, Veronica Bunn, Shu Jin, Caicun Zhou, D. Ross Camidge

Institutions: Dana-Farber Cancer Institute, Emory University, National Taiwan University, Memorial Sloan Kettering Cancer Center, Shanghai Pulmonary Hospital, University of Colorado Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281692354

Cites:

Cited by: 7

Related to: 10